Since nobody else has anything to say, here's some news for anyone still interested in NPRO:
Napro BioTherapeutics Prevails in Administration Patent Suit Against Bristol-Myers Squibb
BOULDER, Colo.--(BUSINESS WIRE)--Aug. 25, 1998--NaPro BioTherapeutics, Inc. (Nasdaq: NPRO - news) announced today that it has received a favorable ruling from the United Kingdom Patent Court in NaPro's patent proceeding against Bristol-Myers Squibb Company [NYSE:BMY - news]. The court ruled in favor of NaPro on NaPro's claim that a patent owned by BMS was invalid in the United Kingdom. The BMS patent in question relates to methods for administration of the anti-cancer agent paclitaxel.
Sterling K. Ainsworth, Ph.D., NaPro's President and Chief Executive Officer, said that, ''We are pleased with the results in this U.K. decision. This ruling removes an important obstacle to the marketing of NaPro paclitaxel in Europe.''
NaPro BioTherapeutics, Inc., headquartered in Boulder, Colorado, is a biopharmaceutical company focused on the development, production and licensing of complex natural-product pharmaceuticals.
biz.yahoo.com
Hollywood |
